A European clinical trial tested sulthiame in patients with moderate to severe obstructive sleep apnea (OSA).[1][2] Patients were divided into four groups: 74 received 100 mg daily, 74 received 200 mg, 75 received 300 mg, and 75 received placebo, in 28 medical centers in Spain, France, Belgium, Germany, and the Czech Republic.[1] The study lasted at least 12 weeks at the target dose.[2] Sulthiame significantly reduced pauses in breathing, daytime sleepiness, and improved blood oxygen levels.[1] At the highest dose of 300 mg, the frequency of pauses in breathing according to the apnea-hypopnea index (AHI) decreased by 39.9%.[1] The drug stimulates the muscles in the upper airways and stabilizes respiratory signals in the brain.[1] The findings could offer an alternative to CPAP machines in tablet form.[1]